secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2024-04-24T23:59:59+00:00
Accession:  0001438533-24-000016
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EU grants conditional marketing authorization for Travere's FILSPARI in IgA nephropathy
--------------------------------------------------------------------------------

- European Commission approved FILSPARI (sparsentan) for adults with primary IgAN with urine protein excretion ≥1.0 g/day or UPCR ≥0.75 g/g.
- Approval covers all EU member states plus Iceland, Liechtenstein, Norway; follows CHMP positive opinion in February 2024.
- Decision based on pivotal Phase 3 PROTECT Study results; FILSPARI already has accelerated approval in the US.
- CSL Vifor holds exclusive commercialization rights in Europe, Australia, New Zealand; expects launch in first European markets in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853324000016/0001438533-24-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853324000016/tvtx-20240424.htm
  HTML page:      https://secwatch.observer/filing/0001438533-24-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer